Canagliflozin Anhydrous: Side Effects, Uses & Monitoring

INVOKANA (canagliflozin) is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Data source
FDA labeling via NIH DailyMed (label 5f76e16f…)
Label version
current
Last reviewed
2026
Side effects

Reported adverse reactions

Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.

No structured frequency data available in current labeling. Consult the official label.

Uses

Labeled uses (from FDA prescribing information)

INVOKANA (canagliflozin) is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). • to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.

Related conditions

Conditions associated with Canagliflozin Anhydrous in labeling

FAQ

Frequently Asked Questions

What is Canagliflozin Anhydrous used for?

FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.

What are the most commonly reported side effects of Canagliflozin Anhydrous?

Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.

Does Canagliflozin Anhydrous require lab monitoring?

Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Canagliflozin Anhydrous.

Where does this information come from?

All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.

Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

Educational content only: The information on Symptom Database.com is for educational purposes and is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Read our full disclaimer.